Perspectives

Clinical Insights on Alzheimer’s and ADHD

Short reflections, clinical notes, and ideas from Dr. Baris Demiralay at the intersection of psychiatry, research, and everyday practice.

Alzheimer’s & Dementia

Early Signs of Alzheimer’s Disease: What Changes Matter?

Occasional forgetfulness is common. The more meaningful warning signs are changes that are new, persistent, and beginning to interfere with everyday life — in memory, planning, language, judgment, navigation, or behavior.

Read More →

February/16/2026

SYMPTOMS

ADHD Beyond Hyperactivity: What the Symptoms Really Look Like

ADHD symptoms go beyond hyperactivity. Inattention, impulsivity, restlessness, and organization problems can appear differently across the lifespan.

Read More →

February/16/2026

ATTENTION & EXECUTIVE FUNCTION

How ADHD Affects Attention, Motivation, and Executive Function

Why can someone with ADHD focus intensely sometimes but struggle at other times? Exploring attention, motivation, time management, and executive function.

Read More →

February/23/2026

DIAGNOSIS

How Is ADHD Diagnosed Today?

ADHD has no single diagnostic test. Clinicians use history, rating scales, impairment, and differential diagnosis to reach an accurate assessment.

Read More →

March/2/2026

RISK REDUCTION

Can Alzheimer’s Risk Be Reduced? What the Evidence Says

There is no guaranteed way to prevent Alzheimer’s disease, but brain health is not entirely outside our control. This guide separates practical risk reduction from exaggerated prevention claims.

Read More →

March/3/2026

ADULT ADHD

Adult ADHD: Why It Can Be Missed Until Later in Life

Adult ADHD can be diagnosed late even though symptoms begin in childhood. Why it is missed, how it presents, and what a careful evaluation considers.

Read More →

March/9/2026

GENETICS

Is ADHD Genetic? What We Know About Risk and Brain Development

ADHD has a strong genetic component, but there is no single ADHD gene. What heritability means, what testing can show, and why genes are not destiny.

Read More →

March/16/2026

NEUROBIOLOGY

How Alzheimer’s Disease Changes the Brain

What begins as microscopic changes in proteins and cell signaling can, over years, disrupt the brain’s communication networks and reshape the systems that support memory, reasoning, language, and behavior.

Read More →

March/18/2026

TREATMENT

ADHD Medications: Stimulants, Nonstimulants, and What Treatment Can Actually Do

Comparing ADHD stimulant and nonstimulant medications, realistic benefits, risks, and monitoring.

Read More →

March/23/2026

EMOTIONAL REGULATION

ADHD and Emotional Regulation: Why Frustration Can Feel So Intense

Emotional dysregulation can accompany ADHD but is not a core diagnostic symptom. Why frustration may escalate quickly and what else clinicians consider.

Read More →

March/30/2026

DIAGNOSIS

How Is Alzheimer’s Disease Diagnosed Today?

A modern Alzheimer’s evaluation is no longer just a memory test. Clinicians combine history, cognitive assessment, imaging, and — when appropriate — biomarkers.

Read More →

April/2/2026

COMORBIDITY

ADHD, Anxiety, Depression, and Sleep: Why Symptoms Overlap

ADHD, anxiety, depression, and sleep problems can all affect concentration. How clinicians distinguish overlapping symptoms and identify comorbidity.

Read More →

April/6/2026

GENETICS

Is Alzheimer’s Disease Genetic? Understanding APOE and Inherited Risk

Genes matter in Alzheimer’s disease, but “genetic” does not usually mean inevitable. Learn what APOE ε4 and family history really mean for risk.

Read More →

April/17/2026

NEUROPSYCHIATRY

Why Does Alzheimer’s Disease Cause Agitation?

Agitation is not simply “bad behavior.” It can emerge from brain changes, unmet needs, medical problems, or environmental stress — often several at once.

Read More →

May/2/2026

NEUROPSYCHIATRY

What Happens Beyond Memory Loss? Behavioral and Psychiatric Symptoms

Depression, anxiety, apathy, psychosis, and sleep disruption can become as clinically important as cognitive decline in Alzheimer’s disease.

Read More →

May/17/2026

TREATMENT

Anti-Amyloid Therapy: Who May Benefit and What Are the Risks?

Lecanemab and donanemab can slow decline in selected early-stage patients, but eligibility depends on biomarkers, MRI monitoring, and ARIA risk.

Read More →

June/1/2026

DIAGNOSIS & BIOMARKERS

Can a Blood Test Detect Alzheimer’s Disease?

A blood draw can now provide clinically useful evidence of Alzheimer-related pathology — but it is not a stand-alone answer to every memory complaint.

Read More →

June/16/2026